Galectin Therapeutics reported $15.83M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Bristol Myers Squibb BMY:US USD 9.12B 1.39B
Galectin Therapeutics GALT:US USD 15.83M 8.35M
Gilead Sciences GILD:US USD 7.63B 2.93B
Idera Pharmaceuticals IDRA:US USD 26.8M 2.32M
Intercept Pharmaceuticals ICPT:US USD 50.52M 62.68M
Regulus Therapeutics RGLS:US USD 24.23M 4.21M
Vital Therapies VTL:US USD 106.74M 33.97M
YTE INCY:US USD 2.95B 260.8M